Fig. 1: Study design, patient deposition and secondary endpoints. | Nature Medicine

Fig. 1: Study design, patient deposition and secondary endpoints.

From: Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

Fig. 1

a, Graphical representation of clinical study design including key inclusion criteria. b, Patient deposition during the phases of the clinical study including screening, preoperative immunotherapy and curative resection. Reasons for screening failure and outcomes of surgery are summarized (*including one patient with single bone metastasis). c, Fraction of patients (n = 60) with microscopically complete (R0, green), microscopically incomplete (R1, purple) and macroscopically incomplete (pleural carcinosis, M1a (PLE), orange) resection of primary lung cancers and, if present, lymph node metastases per study arm. d, Fraction of patients (n = 60) with complete (none), partial response (PR, green), stable (SD, yellow) and progressive disease (PD, red) per RECIST evaluation of CT scans per study arm. e, Fraction of patients (n = 31) with complete (none), partial metabolic response (PMR, green), metabolically stable (SMD, yellow) and metabolically progressive disease (PMD, red) per PERCIST evaluation of positron emission tomography scans per study arm. SoC, standard of care.

Back to article page